Impact factor of 1.143 just released
Impact factor of 1.143 just released for Patient Preference and Adherence, published by Dove Medical Press
A Strong Impact Factor for an Up and Coming Scientific Journal
Thomson Reuters has just released the 2011 Journal Citation Reports® (JCR), showing new impact factors for several of Dove Medical Press journals, including Patient Preference and Adherence. The JCR provides information about highly-cited, peer reviewed publications and is the source of the new Journal Impact Factors.
The 2011 impact factor for the Patient Preference and Adherence (PPA) has been released at 1.143.
Dr. Changyi Chen, PPA Editor-in-Chief, proudly says "It is great news that our journal has received its first impact factor from Thomson-Reuters. Developing a high quality medical journal is truly not an easy task. I am so grateful to the editorial board members, office staff, expert reviewers, and authors. They have all worked very hard to achieve our goals and high standards.”
The PPA publication covers unique medical research areas, has critical review processes, and rapidly publishes quality articles. “We also provide excellent services to our authors and readers as well as the scientific community. We are proud of our work and will do our best to continually improve the quality and impact of our journal,” says Dr. Chen
As Thomson Reuters quotes, "Journal Selection takes place throughout the course of a year and its goal is to identify, evaluate and select the most important and influential International and Regional journals for coverage in Thomson Reuters Web of Knowledge platform. The following year, these data are then analyzed and published in the JCR release, providing a view of how these journals are integrated, through citation, with the scholarly, multidisciplinary literature."
Press is a privately held publisher of 100+ open access
peer-reviewed journals across the broad spectrum of science,
technology and especially medicine. Dove was founded in 2003
and has offices in the United Kingdom and New Zealand, with
an active presence in the USA and a network of agents in
Europe, the Americas, and Southeast